Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab or Icrucumab with Docetaxel in Advanced Transitional Cell Carcinoma
NCT01282463Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2011
- Primary completion
- Feb 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ramucirumab, icrucumab in bladder transitional cell carcinoma (TCC), Transitional cell carcinoma of the urethra, ureter transitional cell carcinoma (UTUC), transitional cell carcinoma of the renal pelvis (TCC), sponsored by Eli Lilly and Company. Started Apr 2011; status: completed.
02
Drugs
ramucirumabicrucumab
03
Conditions
bladder transitional cell carcinoma (TCC)Transitional cell carcinoma of the urethraureter transitional cell carcinoma (UTUC)transitional cell carcinoma of the renal pelvis (TCC)
Beyond the preview
Go deeper on NCT01282463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282463.